UroGen Pharma (URGN) Misses Q3 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. JBLU
4. ANT
5. META
6. SSD
7. AGYS
8. PECO
9. AMKR
10. BX

Go back to UroGen Pharma (URGN) Misses Q3 EPS by 23c

UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment

November 12, 2018 8:00 AM EST

Following a Recent Pre-New Drug Application (NDA) Meeting with the FDA for UGN-101, the Company Has Concluded Patient Enrollment in the OLYMPUS Phase 3 Trial for Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

Breakthrough Therapy Designation (BTD) Previously Granted by the FDA for UGN-101 for the Treatment of LG UTUC

Company On Track to Initiate UGN-101 Rolling NDA Submission to the FDA in Q4 2018 with Completed Submission in Q2 2019 and Potential Approval in 2019

Conference Call Today at 8:30 a.m. Eastern Time

RAANANA, Israel & NEW... More